RxDoctor Payments Data

John Dick Ii, MD

Ophthalmology · Kahului, HINPI 1083762918

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Genentech USA, Inc. accounts for 78.4% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $206, more than ten times the $13 reported in 2021. That places this record below the midpoint for ophthalmology clinicians in HI, where the typical reported total is $2,251.

$295in general payments, 2019–2025

Across 13 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$231
  • Mallinckrodt Hospital Products Inc.$32
  • Amgen$18
  • AbbVie$13

What the payments were for

  • Food & beverage$295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$295 in reported general payments places this provider in the 20th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii →

Medicare billing

Part B allowed, 2024
$614,972
Medicare patients
806
Services billed
9,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost42$25,124
CombiganBrimonidine Tartrate/Timolol39$13,270
Alphagan PBrimonidine Tartrate34$9,730
Latanoprost455$8,079
Prednisolone Acetate150$5,903
VyzultaLatanoprostene Bunod12$4,778
Brimonidine Tartrate127$3,655
Timolol Maleate221$3,472
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,121
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat142$2,447
Travoprost11$2,063
Bepotastine Besilate11$1,709
Ketorolac Tromethamine45$1,297
Azelastine Hcl37$1,220
Acetazolamide ErAcetazolamide17$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$13$48,123115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Kahului

See the full list for Hawaii →

Where these figures come from

Is this you, or does something look wrong? →